German agency BioNTech stated Friday it was racing to ramp up production of its Covid-19 vaccine in Europe, to fill the "gap" left by the dearth of different accredited vaccines.
The vaccine developed by BioNTech and its US associate Pfizer was the primary to be accredited within the European Union in late December.
Countries together with Britain, Canada and the United States accredited the Pfizer/BioNTech vaccine earlier and have since additionally greenlighted jabs by US agency Moderna or Oxford/AstraZeneca, leaving the EU's inoculation drive lagging behind.
"The current situation is not rosy, there's a hole because there's an absence of other approved vaccines and we have to fill this gap with our vaccine," BioNTech co-founder Ugur Sahin informed Der Spiegel weekly.
Criticism of the sluggish tempo of Europe's vaccine rollout has grown louder in current days.
In Germany, the place the main target has been on inoculating aged individuals in care houses, senior medical doctors have complained that hospital employees are being left ready for his or her jabs regardless of being within the precedence teams.
'Basket of suppliers'
France has seen related complaints, prompting the federal government to announce that well being staff aged over 50 may get the shot from Monday – prior to initially deliberate.
Part of the issue is that the EU positioned a comparatively low order of 300 million doses for its 27 member states, and the contract was solely signed in November, later than different international locations.
Fellow BioNTech founder Ozlem Tureci informed Spiegel that the EU had assumed there could be "a basket of different suppliers" to select from, given the worldwide race to develop a pandemic-ending jab.
"Such an approach makes sense. But then at some point it became clear that many would be unable to deliver quickly."
Sahin stated BioNTech aimed to get a brand new manufacturing facility within the German metropolis of Marburg up and operating in February, "far earlier than planned", that ought to then have the opportunity to churn out an extra 250 million doses within the first half of 2021.
Tureci stated they’d additionally struck offers with 5 pharmaceutical producers in Europe to improve production, and negotiations with different specialised corporations are ongoing.
"By the end of January we should have clarity on what and how much more we can produce," Sahin stated.
BioNTech and Pfizer had been initially aiming to ship 1.3 billion doses worldwide this yr, sufficient to immunise 650 million individuals.
based mostly on web site supplies www.rte.ie